BHV-0223 + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Social Anxiety Disorder
Conditions
Social Anxiety Disorder, Performance Anxiety
Trial Timeline
Jan 1, 2017 → Jan 29, 2021
NCT ID
NCT03017508About BHV-0223 + Placebo
BHV-0223 + Placebo is a phase 2/3 stage product being developed by Biohaven for Social Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03017508. Target conditions include Social Anxiety Disorder, Performance Anxiety.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03017508 | Phase 2/3 | Completed |
Competing Products
20 competing products in Social Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY686017 + paroxetine + placebo | Eli Lilly | Phase 2 | 52 |
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Cariprazine + Placebo | AbbVie | Approved | 85 |
| Quetiapine | AstraZeneca | Approved | 85 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Phase 2/3 | 65 |
| Seroquel + Sugar Pill | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Approved | 85 |
| Pristiq + Placebo | Pfizer | Approved | 84 |
| Venlafaxine ER | Pfizer | Phase 3 | 76 |
| Ziprasidone + Sertraline | Pfizer | Phase 2 | 51 |
| Sertraline + Placebo | Pfizer | Approved | 84 |
| Nefazodone | Bristol Myers Squibb | Approved | 84 |
| Escitalopram | Lundbeck | Approved | 82 |
| Cipralex + Placebo | Lundbeck | Phase 2 | 49 |
| VQW-765 + Placebo | Vanda Pharmaceuticals | Phase 3 | 69 |
| PH94B | Vistagen Therapeutics | Phase 3 | 69 |
| Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray | Vistagen Therapeutics | Phase 2 | 44 |
| PH94B Nasal Spray + Placebo Nasal Spray | Vistagen Therapeutics | Phase 3 | 69 |